U.S. FDA flags risk of heart inflammation after Novavax COVID vaccine

Brasil Notícia Notícia

U.S. FDA flags risk of heart inflammation after Novavax COVID vaccine
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 Reuters
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

The U.S. Food and Drug Administration hasraised concerns about a possible risk of heart inflammation from Novavax Inc's COVID-19 vaccine, even as the company's data showed it could reduce the chances of mild-to-severe disease.

COVID-19 vaccine, even as the company's data showed it could reduce the chances of mild-to-severe disease.

The agency said it had requested Novavax to flag myocarditis and another kind of heart inflammation called pericarditis as an "important identified risk" in its materials. The company has not yet agreed to do so. "Despite the wide availability of authorized or approved vaccines, the SARS-CoV-2 pandemic is not well controlled in the U.S. ... there remains a desire for vaccines that have been developed using well-understood technology platforms," it said.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Reuters /  🏆 2. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Novavax hopes its COVID shot wins over FDA, vaccine holdoutsNovavax hopes its COVID shot wins over FDA, vaccine holdoutsGAITHERSBURG, Md. (AP) — Americans may soon get a new COVID-19 vaccine option -- shots made with a more tried-and-true technology than today’s versions. The big question: Why should they care? After long delays, the Food and Drug Administration is expected to decide within weeks whether to authorize Novavax's vaccine.
Consulte Mais informação »

Novavax hopes its COVID shot wins over FDA, vaccine holdoutsNovavax hopes its COVID shot wins over FDA, vaccine holdoutsAmericans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine.
Consulte Mais informação »

Q&A: Novavax hopes its COVID shot wins over FDA, vaccine holdoutsQ&A: Novavax hopes its COVID shot wins over FDA, vaccine holdoutsAmericans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine.
Consulte Mais informação »

U.S. FDA flags risk of heart inflammation after Novavax COVID vaccineU.S. FDA flags risk of heart inflammation after Novavax COVID vaccineThe U.S. Food and Drug Administration hasraised concerns about a possible risk of heart inflammation from Novavax Inc's COVID-19 vaccine, even as the company's data showed it could reduce the chances of mild-to-severe disease.
Consulte Mais informação »

Can Novavax win over vaccine holdouts with its Covid shot?Can Novavax win over vaccine holdouts with its Covid shot?The late entrant into the U.S. vaccination effort uses the same technology seen in vaccines for hepatitis B and shingles, among others.
Consulte Mais informação »



Render Time: 2025-03-01 04:36:19